Earlier compiled-answer archive. This page retains the mixed historical answers and selected retries. The fresh MontMedical Pro Model results and model comparison are in the latest diagnostic review.
The seven completed MontMedical retries replace the older entries in this table. Read the scores, the actual answer excerpts and the limits of this comparison.
How the answers were assessed
One diagnostic review method for both systems.
Each answer receives a holistic editorial score from 0 to 10 in half-point steps, considering the four criteria below. Separate numerical sub-scores or weights were not assigned for this review. A strong, well-supported diagnosis earns credit; extra caveats do not automatically improve a score.
Criterion
Question
Diagnostic accuracy
Does the answer identify and rank the best-supported clinical diagnosis?
Tests and experiments
Does it explain what the supplied measurements, controls and comparisons actually establish?
Appropriate certainty
Does it distinguish a strong diagnosis from an unproved mechanism, cellular identity or causal claim?
Clarity
Does the explanation make the important evidence and remaining questions clear without contradiction?
Which answers, which retries, and what limits?
52 case entries; 51 pairs
The compiled collection contains 52 complete cases, using its original numbering. Cases 12–15 are incomplete in that compilation and are not included. Case 35 has a retained MontMedical answer but no supplied OpenEvidence response; it appears in the table without a competitor score and contributes to neither paired mean nor lead count.
Cases 08, 16, 20, 22, 23, 25 and 28 were rerun because their previous MontMedical answers were rated below 8. All seven new completed diagnosis answers are included, without selecting only the improvements. Six improved to 8.5–9.0; case 22 remains 7.5 because its alternatives conflict with its main evidence review. The prompts were not changed for these retries, reasoning stayed at Medium or lower, and the optional treatment workflow was disabled. Prior answers, grading notes and competitor answers were not supplied to the new runs.
The displayed collection now contains 14 current-workflow MontMedical answers and 38 historical MontMedical/Ark answers from different revisions. Three historical entries, cases 10, 11 and 27, are diagnostic-writer exports whose final displayed versions are unverified. Earlier case descriptions include normalised reconstructions; identical original input prompts are not established for every pair. OpenEvidence's original run dates and full settings are unverified.
Diagnostic answer quality, not clinical efficacy
The assessment covers the initial diagnostic discussion, Further evidence and alternatives where retained. Treatment recommendations and Learning were not graded. These are selected synthetic development cases, some used in earlier work; they are not an unseen held-out test. The review is retrospective and unblinded, with AI assistance and product names visible. It was not scored by an independent blinded clinical panel. Key criticisms were checked against the case facts and selected primary sources, but every citation was not independently audited.
The paired means use the unrounded totals and are displayed to two decimal places; individual case scores use one decimal. That arithmetic does not make small score differences statistically established or convert quality judgments into diagnostic accuracy or patient-outcome measurements.
Actual words, with source limits visible
The excerpts below are contiguous passages checked against the saved answers. Citation markers, Markdown styling, escaping and whitespace are normalised for display; clinical wording is not rewritten. Longer passages are truncated at a word boundary and labelled as excerpts. The scores and surrounding assessments are editorial judgments. The earlier eleven-case and eight-case reports overlap this material and must not be added to its case count as independent evidence.
The seven older MontMedical answers rated below 8 were rerun through the current diagnosis workflow. All seven completed retries replace those entries here, including case 22, which remains at 7.5. OpenEvidence's supplied answers and scores are unchanged.
OpenEvidence · 51 paired answers8.17/10
MontMedical · 51 paired answers8.83/10
35 MontMedical leads · 7 OpenEvidence leads · 9 ties. These are editorial answer-quality scores, not percentages of correct diagnoses.
The same four review criteria: diagnostic accuracy, interpretation of tests and experiments, appropriate certainty, and clarity. Treatment was not graded. Read the method and limits.
Scores out of 10 · 52 cases retained · 51 paired answers · seven new MontMedical retries included
Both identify DADA2. MontMedical more clearly separates a strong clinical diagnosis from biochemical/genetic confirmation; OpenEvidence overstates some exclusions.
Both favour dual amyloid disease but over-attribute cardiac progression before definitive tissue typing. OpenEvidence additionally prints a prognostic stage without the required troponin input.
The final MontMedical evidence section correctly identifies PRDX1-mediated epi-cblC as an untested prediction; its earlier MTHFR wording is less precise. OpenEvidence reaches the same mechanism but treats it too definitively.
MontMedical better distinguishes predicted patient-specific findings from the known mechanism. OpenEvidence incorrectly says every reported case has thymoma.
MontMedical preserves the unproved identity of the anti-FH antibody and paraprotein. OpenEvidence leads with that identity as established before later acknowledging the gap.
MontMedical better separates a suspected organism from tissue proof and distinguishes inflammatory psoas tissue from an abscess; both contain some overconfident causal wording.
The new answer identifies histiocytic sarcoma while keeping common ancestry unproved. It explicitly requests verified tumour nuclei and controls for engulfed/adherent lymphoma cells, rather than treating bulk fusion reads as lineage proof.
MontMedical better separates donor origin, minimum phylogeny and unknown event timing. OpenEvidence overinterprets negative fibroblasts and failure to detect later mutations in the graft.
Both identify somatic rescue. MontMedical uses the sorted-genotype data more explicitly, but both overstate structural phasing or attribution to CXCR4 alone.
Both identify the donor liver as the relevant testing compartment. Both contain some overly categorical exclusion language; the graft genotype remains unconfirmed.
The new answer prioritises enterovirus initially and quantitatively demonstrates the integrated HHV-6 copy-number explanation. The initial paragraph misstates the 0.50 viral/RPP30 ratio as copies per cell; the final evidence section correctly converts it to one viral copy per diploid cell.
Both calculate the conflicting indices and reject proven mixed adenoma. MontMedical is more careful about protocol-specific validation; neither concentration alone measures secretion flux.
Both identify masked PV. OpenEvidence mixes older/ICC red-cell-mass criteria with a WHO-5 calculator that does not show the qualifying haemoglobin/haematocrit input.
The new answer leads with the acquired CaSR-related phenotype and correctly separates native binding, opposing endpoint effects, individual G-protein coupling, antibody identity and in-vivo causation. It no longer prioritises repeat surgery as the diagnostic solution.
Both unify PAP, HLH, tubular disease and hyperammonaemia. MontMedical handles treatment-confounded sampling clearly; OpenEvidence is more categorical and asks for off-therapy biochemical retesting.
The main evidence review improves and appropriately requests review of angiographic adequacy. However, the alternatives section still treats medullary extension, low-cell/high-protein CSF and lack of abrupt steroid deterioration as arguments against a vascular fistula, and conflicts with the main assessment. The full displayed answer remains below 8.
The new answer correctly calculates electrolyte-free water clearance, net water deficit, cation retention and the sodium trajectory, and preserves uncertainty about untreated AVP function. It still omits the supplied nitrogen-pool reconciliation, and its alternatives wording conflates recurrent central deficiency with desmopressin resistance.
Both identify the multisystem microvasculopathy. MontMedical better separates a suggestive phenotype from molecular confirmation; OpenEvidence makes some overly broad exclusions and speculative family-history inferences.
The new answer identifies an acquired IgG-associated capillary LPL-capture defect, leaves the antigen and transendothelial transport unproved, rejects direct anti-LPL attribution from the whole-plasma assay, and correctly recognises pseudohyponatraemia.
Both recognise the Fe-S enzyme pattern and deep-intronic testing gap. Neither fully establishes the genotype or completes the physiological proof chain.
OpenEvidence explains the osmotic-fragility direction and downstream Gardos blockade more clearly. The MontMedical export corrects an erroneous initial description but retains presentation clutter.
The new answer distinguishes an IgG3-kappa-restricted pattern from one unique clonal protein, preserves possible contribution by the original clone, treats undetectable as below the assay limit, and does not use relapse to prove that the clone is incidental.
Both recognise acquired brain sagging despite normal opening pressure. MontMedical gives a more precise localisation protocol and positive imaging criterion.
Both identify APRT deficiency and the need to identify the crystals. OpenEvidence handles the transfusion-confounded enzyme assay but incorrectly treats normal serum urate as evidence against uric-acid stones.
Both recognise nodopathy despite axonal histology and post-exchange negative testing. OpenEvidence more specifically develops CNTN1 and the renal antigen-link investigation.
Both recognise spontaneous HIT. MontMedical preserves uncertainty about adrenal venous thrombosis and argatroban exposure; OpenEvidence treats underdosing as demonstrated.
MontMedical correctly distinguishes C-terminal fragments from intact FGF23. OpenEvidence miscalls a measurable 6 pg/mL result below quantification and labels biological fragment excess an assay artefact.
MontMedical better preserves coexistence and the motif-specific assay boundary. OpenEvidence mislabels the vestibular test and overstates some genetic and phenotypic conclusions.
Both final assessments identify the stimulus-specific oxidase disorder. OpenEvidence explains the neutrophil–B-cell discrepancy more directly; MontMedical initially leads with Crohn disease before correcting its ranking.
MontMedical separates suspected tumour microvascular disease from unidentified aspirate cells and unproved vascular architecture. OpenEvidence overstates what the haemodynamics prove and incorrectly says transbronchial biopsy samples the wrong compartment.
Both recognise acquired esterification inhibition, explain why the negative blot and failed depletion do not exclude an antibody, and separate IgG inhibition from attribution to the marrow clone.
MontMedical reaches the correct final diagnosis and addresses normal circulating flavins, but its initial length-dependent/ETF-led formulation is misleading. OpenEvidence prioritises the syndrome better, while overlooking that articulation-independent audiometry was already done.
MontMedical explicitly distinguishes the factor-II preparation, late peptide cleavage, active thrombin, complex formation and clinical heparin response. OpenEvidence names the leading disorder but repeatedly describes the unproved resistance mechanism as established.
MontMedical separates preserved enzyme assembly and heparin binding from untested endplate retention, and low-positive antibody detection from pathogenicity. OpenEvidence prematurely declares the antibody false and the precise MuSK-interaction defect localised.
MontMedical separates the exact published JAK3 association, unknown carrier-cell identity and unproved drug responsiveness. OpenEvidence gets the entity right but prematurely labels the blood signal incidental and the disease GI-confined.
MontMedical corrects both resistance inputs and obtains PVR 1.74 WU. OpenEvidence calculates pulmonary flow correctly later, but keeps thermodilution output in the resistance calculation and incorrectly labels combined pre/post-capillary disease.
Both identify CANOMAD and reject the initial CSF result as proof of infiltration. MontMedical quantifies expected blood carryover and preserves the unproved identity of the antibody-producing clone; OpenEvidence assumes that clone is the source.
Both identify the FV-short mechanism. MontMedical explains why co-depletion does not isolate either protein and proposes controlled V1-versus-wild-type RNA testing; OpenEvidence treats the candidate variant and exact cooperative mechanism as already proved.
Both recognise acquired EPP and transfusion dilution. MontMedical also reconciles the zinc-protoporphyrin denominator and FECH dosage quantitatively; OpenEvidence overassigns the deletion to the SF3B1 clone and calls combined-treatment worsening causal.
Both distinguish the resolved fluid episode from acquired ON-bipolar dysfunction and identify the knockout floor effect, total-IgG specificity gap and artificial delivery route. Treatment recommendations are outside this diagnostic score.
Both correctly accept the pathogenic CPT2 genotype. MontMedical recognises that malonyl-resistant mixed activity has not been validated as native CPT II activity; OpenEvidence repeatedly treats it as CPT-II-specific and infers an enzyme deficit from it.
Both explain the non-exclusionary gradient and inadequate biopsy. MontMedical correctly dates the thrombus from the prior patent scan; OpenEvidence introduces an unproved older thrombotic component and overstates azathioprine causation.
Both correctly convert haemoglobin percentages and oxygen delivery. OpenEvidence more directly interprets the partial-C genotype; MontMedical initially keeps anti-Jkb plausible despite verified Jkb-negative units, then correctly downgrades it later.
Both reject scan/genotype/amenability as independent proof of amyloid or Fabry disease. MontMedical better specifies expert review for curvilinear bodies; OpenEvidence is too categorical that negative sampled myocardium excludes all cardiac amyloid.
Both reconstruct the 21.1% to 2.5% blood VAF, the approximately 13% sampling-miss probability, and the different implications of monosomy 7 and copy-neutral rescue. Both correctly reject blood-only clearance of the related donor.
Both identify transferable IgG-mediated signalling inhibition and inducible macrolide resistance. MontMedical keeps assay interference separate from biological inhibition and avoids assigning the relapse chiefly to either host or organism; OpenEvidence overstates that relative attribution.
Mean of the 51 paired answers
8.17
8.83
Case 35 has no OpenEvidence answer and is excluded from both means.
Published and assessed by MontMedical. AI-assisted, unblinded editorial review of selected development cases. Historical answers and current runs are mixed; the seven retries were selected because of their earlier low scores. This is not a uniform current-version benchmark or independent clinical validation.
103 passages from the selected answers are reproduced below. Open each case to compare the wording. Private account records, internal prompts and credentials are not published.
Compiled case 01
DADA2
Our assessment: Both identify DADA2. MontMedical more clearly separates a strong clinical diagnosis from biochemical/genetic confirmation; OpenEvidence overstates some exclusions.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
This presentation — childhood-onset recurrent fevers, livedo racemosa, a "Castleman-like" lymph node (regressed germinal centers with interfollicular plasmacytosis, a recognized but under-appreciated DADA2 finding), biopsy-proven cutaneous/medium-vessel polyarteritis nodosa, recurrent lacunar and deep grey-matter strokes with a normotensive thalamic hemorrhage, pure red-cell aplasia, evolving hypogammaglobulinemia with recurrent infections, and an affected sibling with an overlapping phenotype who died of sepsis after immunosuppression — is the textbook multisystem phenotype of deficiency of adenosine deaminase 2 (DADA2), an autosomal recessive monogenic vasculitis/autoinflammatory syndrome caused by biallelic loss-of-function variants in ADA2 (formerly CECR1).
Contiguous excerpt.
MontMedical · 9.0/10
Current MontMedical Pro · 17 November 2026
The clinical syndrome is childhood-onset systemic inflammation with livedo, biopsy-proven necrotising medium-vessel arteritis, recurrent strokes and haemorrhage, pure red-cell aplasia, and immunodeficiency. The leading provisional diagnosis is deficiency of adenosine deaminase 2 (DADA2), supported by the PAN-pattern vasculitis, early cerebrovascular disease, cytopenias, and immune dysfunction; the accurately described Castleman-like node does not require a separate cause.
Our assessment: Both favour dual amyloid disease but over-attribute cardiac progression before definitive tissue typing. OpenEvidence additionally prints a prognostic stage without the required troponin input.
Read the actual answer excerpts
OpenEvidence · 7.5/10
Supplied OpenEvidence answer; original run date and settings unverified
This case describes coexisting AL and ATTR cardiac [amyloidosis] (dual/mixed amyloidosis) — the hematologic complete response explains the renal improvement, but the persistent and worsening cardiac findings despite clearance of the lambda clone point to an untreated wild-type ATTR component driving the cardiomyopathy.
Contiguous excerpt.
MontMedical · 8.0/10
Historical MontMedical / Ark answer
The clinical presentation and longitudinal course strongly point to coexistent (dual) systemic amyloidosis: specifically Wild-Type Transthyretin Cardiac Amyloidosis (ATTRwt-CM) driving the progressive infiltrative cardiomyopathy, occurring alongside successfully treated Renal Light-Chain (AL) Amyloidosis secondary to an IgG-lambda plasma cell dyscrasia [C2, C4, ].
Our assessment: The final MontMedical evidence section correctly identifies PRDX1-mediated epi-cblC as an untested prediction; its earlier MTHFR wording is less precise. OpenEvidence reaches the same mechanism but treats it too definitively.
Read the actual answer excerpts
OpenEvidence · 8.0/10
Supplied OpenEvidence answer; original run date and settings unverified
Late-onset cobalamin C (cblC) deficiency caused by digenic "epi-cblC" disease — a heterozygous pathogenic MMACHC variant (p.Arg161Gln) in trans with a cis-acting PRDX1 variant that produces an aberrant antisense transcript, hypermethylates the MMACHC promoter on the second allele, and silences its expression — is the diagnosis that unifies this entire presentation. Combined elevation of homocysteine and methylmalonic acid with low-normal methionine, normal/high serum B12, and macrocytic/megaloblastoid marrow is the biochemical signature of a combined remethylation defect; only cblC-type disorders (and the related cblD/F/J, or transcriptional regulator defects such as cblX/cblK) produce this pattern together with normal B12 levels, which rules out dietary or absorptive B12 deficiency. The markedly elevated MMA
Contiguous excerpt: passage continues.
MontMedical · 8.5/10
Historical MontMedical / Ark answer
Most likely complete diagnosis: cblC-type methylmalonic aciduria with homocystinuria (epi-cblC) — compound genetic-epigenetic heterozygosity at the MMACHC locus: one pathogenic MMACHC c.482G>A, p.(Arg161Gln) allele (demonstrated) plus a PRDX1-mediated MMACHC promoter epimutation (predicted), with homozygous MTHFR c.665C>T as a modifying factor.
Our assessment: MontMedical better distinguishes predicted patient-specific findings from the known mechanism. OpenEvidence incorrectly says every reported case has thymoma.
Read the actual answer excerpts
OpenEvidence · 8.0/10
Supplied OpenEvidence answer; original run date and settings unverified
- Selective, acquired tri-hormonal pattern: isolated GH, PRL, and TSH deficiency with intact ACTH/cortisol, LH/FSH/testosterone, and posterior-pituitary function is the defining signature of anti-PIT-1 hypophysitis, reflecting autoimmune attack restricted to PIT-1 (POU1F1)-dependent lineages rather than the whole gland. - Normal pituitary MRI: unlike classic lymphocytic hypophysitis, imaging in anti-PIT-1 disease is typically normal or only mildly atrophic — no enlargement, stalk thickening, or mass — which matches the series of reported cases. - Associated autoimmune background: patients with this syndrome frequently carry other organ-specific autoimmunity (GAD65-positive autoimmune diabetes, autoimmune thyroiditis), fitting a polyautoimmune phenotype linked to thymoma rather than classical APS-1 (which centers on candidiasis, hypoparathyroidism, and Addison's disease —
Contiguous excerpt: passage continues.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
This 61-year-old man presents with an acquired, selective anterior pituitary deficiency involving GH, prolactin, and TSH—sparing ACTH and gonadotroph function—in the setting of a WHO type B2 thymoma. The pattern of combined GH, PRL, and TSH deficiency with preserved ACTH and gonadotrophs is the hallmark of anti-PIT-1 hypophysitis (anti-PIT-1 antibody syndrome), a paraneoplastic autoimmune condition classically associated with thymoma . The normal childhood growth and puberty, adult-onset diabetes (LADA), and the absence of developmental or genetic explanations support an acquired autoimmune process rather than congenital combined pituitary hormone deficiency. The prior attribution of discordant TSH to primary thyroiditis is now better explained by central hypothyroidism from PIT-1 autoimmunity, given the
Our assessment: MontMedical preserves the unproved identity of the anti-FH antibody and paraprotein. OpenEvidence leads with that identity as established before later acknowledging the gap.
Read the actual answer excerpts
OpenEvidence · 8.0/10
Supplied OpenEvidence answer; original run date and settings unverified
This represents monoclonal gammopathy of renal significance (MGRS) in which a lambda-restricted paraprotein functions as a factor H–blocking autoantibody, producing a dual phenotype of [C3 glomerulopathy] with episodic complement-mediated thrombotic microangiopathy (TMA) — a recognised but unusual presentation in which the same clone drives chronic C3-dominant membranoproliferative injury and, during flares, acute TMA with cutaneous vascular C5b-9 deposition.
Contiguous excerpt.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
This 62-year-old man presents with a complex, relapsing renal phenotype that began as C3-dominant glomerulonephritis (C3GN) and later evolved into concurrent thrombotic microangiopathy (TMA), all in the setting of a slowly rising IgG-lambda monoclonal gammopathy. The first biopsy showed a membranoproliferative pattern with bright C3 staining and electron-dense deposits, meeting criteria for C3 glomerulopathy [C1–C6 context]. The subsequent TMA episodes—with schistocytes, thrombocytopenia, normal ADAMTS13, and negative Shiga toxin—fit the clinical definition of atypical HUS (aHUS), a complement-mediated TMA C4C5. The skin biopsy showing vascular C3 and C5b-9 staining without immunoglobulin further supports a systemic complement-driven process.
Our assessment: MontMedical better separates a suspected organism from tissue proof and distinguishes inflammatory psoas tissue from an abscess; both contain some overconfident causal wording.
Read the actual answer excerpts
OpenEvidence · 7.5/10
Supplied OpenEvidence answer; original run date and settings unverified
This presentation represents chronic Q fever (Coxiella burnetii) producing both immune-complex-mediated systemic vasculitis/glomerulonephritis and, later, culture-negative infection of the aortic graft with contiguous spondylodiscitis and psoas abscess.
Contiguous excerpt.
MontMedical · 8.5/10
Historical MontMedical / Ark answer
This 66-year-old man’s presentation is best framed as a culture-negative, immune-complex–mediated systemic illness complicating a prosthetic aortic graft, with a striking sequence of events: an initial cryoglobulinemic vasculitis with MPGN that responded to immunosuppression, followed by progressive constitutional decline and PET/CT evidence of graft-associated infection with contiguous vertebral and psoas inflammation. The key diagnostic tension is whether the cryoglobulinemic syndrome was a primary autoimmune process or an immunologic epiphenomenon of an occult chronic infection—most plausibly *Coxiella burnetii*—given the prior undiagnosed febrile hepatitis-pneumonitis illness, the polyester graft, and the now-demonstrated perigraft inflammatory mass . The clinical pattern of culture-negative vascular graft infection with fever, weight loss, and elevated inflammatory markers is
Our assessment: MontMedical explicitly requires non-blood confirmation and phasing. OpenEvidence treats constitutional status and cis rescue as established.
Read the actual answer excerpts
OpenEvidence · 7.5/10
Supplied OpenEvidence answer; original run date and settings unverified
This presentation is diagnostic of SAMD9L-associated [ataxia-pancytopenia syndrome] (APS), with somatic genetic rescue (SGR) explaining the discordance between hematologic recovery and progressive neurologic decline, and with the deep sequencing findings representing classic low-level germline mosaicism missed by standard filters.
Contiguous excerpt.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
The clinical pattern is a childhood-onset, spontaneously remitting and relapsing bone marrow failure with a transient monosomy 7 clone that later converts to paternal uniparental disomy (copy-neutral LOH) of 7q, followed by a progressive cerebellar ataxia with pyramidal signs. The combination of hematologic remission despite clonal expansion, the paternal 7q haplotype retention, and the later neurologic syndrome strongly suggests a germline or early somatic disorder of a 7q growth-repressor gene, with the low-VAF truncating variants in the interferon-responsive gene at 7q21.2 representing candidate somatic rescue events rather than primary drivers. The leading diagnostic direction is a SAMD9L-related ataxia-pancytopenia syndrome (ATXPC) spectrum disorder, given the hematologic-ataxia overlap and the known phenomenon
Our assessment: The new answer identifies histiocytic sarcoma while keeping common ancestry unproved. It explicitly requests verified tumour nuclei and controls for engulfed/adherent lymphoma cells, rather than treating bulk fusion reads as lineage proof.
Read the actual answer excerpts
OpenEvidence · 5.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Secondary (lymphoma-associated) histiocytic sarcoma, transdifferentiated from the IGH::BCL2/EZH2-Tyr646-mutated follicular lymphoma clone, presenting as malignant histiocytosis-driven haemophagocytic lymphohistiocytosis (HLH) is the most likely explanation for this picture.
Contiguous excerpt.
MontMedical · 9.0/10
Current MontMedical Pro · 17 November 2026 · selected retry
The low-level EZH2 p.Tyr646 and IGH::BCL2 reads in the mass do not establish that its histiocytic tumour shares a clone with the lymphoma. The inguinal lymphoma carries EZH2 p.Tyr646, and the mass contains admixed lymphoma cells as well as intact lymphocytes engulfed by malignant histiocytes; both can contribute DNA to bulk or incompletely purified material. Compare the lymphoma with histologically selected tumour nuclei from the mass, using controls that exclude adherent or engulfed lymphocytes and an orthogonal, cell-localized assay for the IGH::BCL2 breakpoint. A shared breakpoint in verified tumour nuclei would support common ancestry; detection confined to lymphoma cells would not.
Our assessment: MontMedical better separates donor origin, minimum phylogeny and unknown event timing. OpenEvidence overinterprets negative fibroblasts and failure to detect later mutations in the graft.
Read the actual answer excerpts
OpenEvidence · 7.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Mechanism. The donor, though clinically well, harboured an occult ageing-associated clonal haematopoiesis clone carrying SRSF2 P95H and a TET2 frameshift mutation — both canonical, co-occurring CHIP/CCUS drivers. This clone was present at low variant allele fraction in the mobilised stem-cell graft and engrafted along with normal donor haematopoietic stem cells. Within the transplant recipient, the clone acquired additional cooperating hits — IDH2 R140Q, a RUNX1 frameshift, del(7q), and trisomy 8 — none of which are present in the archived donor graft or in the donor's current blood, indicating these lesions arose post-transplant in the recipient's marrow microenvironment. The combination of SRSF2/TET2/IDH2 with RUNX1 mutation and complex cytogenetic lesions (del7q, +8)
Contiguous excerpt: passage continues.
MontMedical · 9.0/10
Current MontMedical Pro · 17 November 2026
The patient has a second acute myeloid leukaemia with cytopenias and a genetic profile distinct from his original AML. The leading diagnosis is donor-cell AML arising from a transmitted donor haematopoietic clone: short tandem repeat testing establishes donor origin, and archived donor stem-cell material shares the recipient’s SRSF2 and TET2 variants. This is not relapse of the recipient’s original AML; the recipient’s pre-transplant fibroblasts and the donor’s buccal DNA argue against recipient-derived disease and a germline donor syndrome, respectively.
Our assessment: Both identify somatic rescue. MontMedical uses the sorted-genotype data more explicitly, but both overstate structural phasing or attribution to CXCR4 alone.
Read the actual answer excerpts
OpenEvidence · 7.5/10
Supplied OpenEvidence answer; original run date and settings unverified
The deleted chromosome 2 segment carries the mutant (CXCR4 R334X) allele, not the wild-type copy. This can be inferred from the phenotype itself even though conventional copy-number/breakpoint analysis alone cannot phase the deletion: the correction is only biologically plausible if the deletion removed the disease allele and left a single functional wild-type CXCR4, rendering the chromothriptic clone CXCR4 haploinsufficient (hemizygous for WT) rather than nullizygous. This is exactly the mechanism reported in WHIM-09, in whom chromothripsis deleted the R334X allele along with \~163 contiguous genes on one copy of chromosome 2, within a single hematopoietic stem cell (HSC). Complete biallelic loss of CXCR4 is not compatible with normal HSC function,
Contiguous excerpt: passage continues.
MontMedical · 8.0/10
Historical diagnostic-writer export; final displayed version unverified
The established syndrome is WHIM syndrome characterized by warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis, with the leading disease being a heterozygous CXCR4 gain-of-function disorder confirmed by the familial p.Arg334Ter variant. The clinical phenotype aligns with this diagnosis across three affected family members, although the mother exhibits atypical spontaneous clinical improvement in middle age coincident with hematologic changes.
Our assessment: Both identify the donor liver as the relevant testing compartment. Both contain some overly categorical exclusion language; the graft genotype remains unconfirmed.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Donor-derived (graft) ornithine transcarbamylase deficiency is the diagnosis that unifies this picture: recurrent, trigger-provoked hyperammonaemic crises (steroids plus high-protein feeding, GI bleed, fasting) in a liver allograft with otherwise preserved synthetic function, biochemistry showing high glutamine (1,486 µmol/L), very low citrulline (4 µmol/L), low-normal arginine/ornithine, markedly elevated urine orotic acid, low BUN, and respiratory alkalosis — the classic proximal urea-cycle signature of OTC deficiency. [1-2] The donor history (lifelong meat avoidance, postpartum confusion, a maternal relative who died with postpartum cerebral oedema) describes a textbook heterozygous OTCD carrier, since pregnancy/postpartum catabolism is a recognised precipitant in carrier females, who can be entirely asymptomatic at other times and pass routine donor
Contiguous excerpt: passage continues.
MontMedical · 8.5/10
Historical diagnostic-writer export; final displayed version unverified
The established syndrome is late-onset hyperammonemic encephalopathy following liver transplantation, and the leading disease is a donor-derived urea cycle disorder manifesting in the allograft. The clinical presentation of recurrent ammonia elevation with normal inter-crisis levels, combined with preserved graft synthetic function and patent vasculature, localizes the metabolic defect to the transplanted liver rather than recipient systemic pathology or structural graft complications.
Our assessment: The new answer prioritises enterovirus initially and quantitatively demonstrates the integrated HHV-6 copy-number explanation. The initial paragraph misstates the 0.50 viral/RPP30 ratio as copies per cell; the final evidence section correctly converts it to one viral copy per diploid cell.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
The RPP30-normalised data settle this. Before treatment, CSF HHV-6 DNA was 62,000 copies/mL against 124,000 RPP30 copies/mL — a ratio of exactly 0.5. After 21 days of ganciclovir, HHV-6 fell to 17,000 and RPP30 to 34,000 — the ratio is still 0.5. Because RPP30 has two copies per diploid cell, a HHV-6:RPP30 ratio of 0.5 corresponds to exactly one HHV-6 genome copy per nucleated cell — the molecular signature of germline-integrated virus present in every cell, not productive replication. [1-2] The apparent "virological response" simply tracked the fall in CSF leukocytes (64→18 cells/µL, a ~3.5-fold drop, matching the ~3.6-fold fall in both HHV-6 and RPP30 copies) — i.e., fewer integrated
Contiguous excerpt: passage continues.
MontMedical · 8.5/10
Current MontMedical Pro · 17 November 2026 · selected retry
Inherited integration is established by the telomeric HHV-6B junction shared with her daughter, positive hair-follicle DNA and pre-treatment blood DNA. The CSF HHV-6/RPP30 ratio remained 0.50: with two RPP30 copies per cell, this is approximately one viral copy per diploid cell both before and after ganciclovir. If unchanged, the post-treatment RPP30 value predicts 17,000 viral copies/mL, exactly the observed value; thus the fall from 62,000 is explained by fewer cells, not a demonstrated specific antiviral effect. The blood decline is also compatible with falling leukocytes: 4.8 million × 2.1/4.9 predicts about 2.06 million copies/mL, close to the observed 2.0 million, assuming a stable viral copy count per leukocyte.
Our assessment: Both calculate the conflicting indices and reject proven mixed adenoma. MontMedical is more careful about protocol-specific validation; neither concentration alone measures secretion flux.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
This AVS does not establish right-sided lateralization — the pattern described is classic for "reverse lateralization" caused by an autonomously cortisol-cosecreting adenoma, and the cortisol-based result the initial report relied on is very likely an artifact rather than a true localization. Neither the second endocrinologist's "two separate tumours" interpretation nor the third clinician's claim of a "proven" mixed tumour can be confirmed from the data given; what the numbers do support is a left-adrenal origin for both abnormalities, but as a probable rather than a proven conclusion. [1-3]
Contiguous excerpt.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
Further evidence Diagnostic assessment: Clinical picture The patient has biochemically established primary aldosteronism with suppressed renin and nonsuppressible aldosterone on seated saline suppression testing. Autonomous ACTH-independent cortisol secretion is documented by failure to suppress on repeated overnight 1-mg dexamethasone suppression tests with suppressed morning ACTH and low DHEAS, in the absence of overt clinical Cushing syndrome and with normal 24-hour urinary free cortisol. Additional findings Adrenal CT demonstrates bilateral nodules: a 2.7-cm homogeneous left adrenal nodule measuring 6 HU and a 1.0-cm homogeneous right adrenal nodule measuring 8 HU on unenhanced imaging. Simultaneous unstimulated adrenal venous sampling demonstrated bilateral successful cannulation by local cortisol selectivity criteria, with adrenal-to-peripheral cortisol ratios
Our assessment: Both correctly use regional wedge discordance to prioritise pulmonary vein obstruction and request dedicated venous imaging.
Read the actual answer excerpts
OpenEvidence · 9.0/10
Supplied OpenEvidence answer; original run date and settings unverified
Multivessel post-ablation pulmonary vein stenosis/occlusion — affecting the left pulmonary veins and the right superior pulmonary vein — is the leading diagnosis, with the physiology previously labelled "precapillary PH" actually reflecting unrepresentative sampling of the one unobstructed vein (right lower lobe).
Contiguous excerpt.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
Further evidence Diagnostic assessment: Clinical picture The patient presents with progressive hypoxaemic respiratory failure, a severely reduced DLCO of 35% predicted, and precapillary-range pulmonary arterial hypertension on initial right-heart catheterisation (mean pulmonary artery pressure 38 mmHg). Additional findings Repeat invasive catheterisation demonstrated marked regional variation in pulmonary artery wedge pressure, with elevated pressures in the left upper lobe (27 mmHg), left lower lobe (25 mmHg), and right upper lobe (23 mmHg), contrasting with a normal right lower-lobe wedge pressure (10 mmHg) and normal left ventricular end-diastolic pressure (9 mmHg). Bronchoalveolar lavage from the left lung demonstrated numerous haemosiderin-laden macrophages confirming prior alveolar bleeding, while ANCA and anti-GBM antibodies were negative
Our assessment: Both identify masked PV. OpenEvidence mixes older/ICC red-cell-mass criteria with a WHO-5 calculator that does not show the qualifying haemoglobin/haematocrit input.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Here is the WHO diagnostic criteria calculator for polycythaemia vera applied to this case:
Contiguous excerpt.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
The leading diagnosis is polycythaemia vera, presenting with splanchnic vein thrombosis and an expanded plasma volume obscuring absolute erythrocytosis on routine blood counts. Why it fits
Our assessment: The new answer leads with the acquired CaSR-related phenotype and correctly separates native binding, opposing endpoint effects, individual G-protein coupling, antibody identity and in-vivo causation. It no longer prioritises repeat surgery as the diagnostic solution.
Read the actual answer excerpts
OpenEvidence · 8.0/10
Supplied OpenEvidence answer; original run date and settings unverified
It is based on only the IP1/Gq-PLC readout, which is indeed increased (176% vs control), but it ignores the ERK1/2 readout, which is markedly suppressed (31–34% of control) and is unaffected by mock or parental-cell adsorption, only normalizing after adsorption on CaSR-expressing cells — proving the ERK suppression is CaSR-antibody-specific. CaSR normally suppresses PTH secretion through both Gq/11 and pertussis toxin-sensitive Gi/o-ERK pathways. [7] An antibody that potentiates Gq/IP1 signaling while blocking the Gi/ERK arm is a biased allosteric modulator, not a conventional agonist, and its net physiological effect on the parathyroid gland is loss of CaSR-mediated inhibitory tone on PTH secretion — i.e., functionally it behaves like a blocking
Contiguous excerpt: passage continues.
MontMedical · 9.0/10
Current MontMedical Pro · 17 November 2026 · selected retry
The focal imaging and intraoperative PTH fall are real evidence that the removed gland contributed PTH, but they do not establish autonomous disease or explain the persistent hypercalcaemia by themselves. Hydration accompanied the transient calcium normalization, and pathology could not distinguish an adenoma from a gland responding to an altered regulatory environment. Residual multigland disease or coexisting primary hyperparathyroidism remains possible despite nonlocalizing subsequent imaging; renewed endocrine and surgical review should weigh that possibility against the acquired CaSR phenotype before another operation.
Our assessment: Both unify PAP, HLH, tubular disease and hyperammonaemia. MontMedical handles treatment-confounded sampling clearly; OpenEvidence is more categorical and asks for off-therapy biochemical retesting.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Lysinuric protein intolerance (LPI), an autosomal-recessive defect of the dibasic amino acid transporter y⁺LAT1 (SLC7A7), unifies all three "separate" chronic problems and explains the acute presentation.
Contiguous excerpt.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
Further evidence Diagnostic assessment: Clinical picture The patient's multisystem presentation—comprising postprandial encephalopathy with severe hyperammonemia following protein loading, secondary hemophagocytic lymphohistiocytosis (HLH), pulmonary alveolar proteinosis, proximal renal tubular dysfunction, and severe osteoporosis—is most consistently explained by lysinuric protein intolerance (LPI). Additional findings The patient developed acute encephalopathy with vomiting, tachypnoea, respiratory alkalosis, and severe hyperammonemia of 326 µmol/L 36 hours after escalating enteral protein feeding to approximately 1.3 g/kg/day, with normal bilirubin and INR and no portosystemic shunt. The constellation of prolonged cytopenias, hyperferritinemia, hypertriglyceridemia, splenomegaly, elevated soluble IL-2 receptor, and bone marrow hemophagocytosis fulfills diagnostic criteria for hemophagocytic lymphohistiocytosis, which is a recognized complication of lysinuric protein intolerance. The
Our assessment: The main evidence review improves and appropriately requests review of angiographic adequacy. However, the alternatives section still treats medullary extension, low-cell/high-protein CSF and lack of abrupt steroid deterioration as arguments against a vascular fistula, and conflicts with the main assessment. The full displayed answer remains below 8.
Read the actual answer excerpts
OpenEvidence · 8.0/10
Supplied OpenEvidence answer; original run date and settings unverified
Current MontMedical Pro · 17 November 2026 · selected retry
She has a severe, progressive longitudinally extensive cervical myelopathy extending into the lower medulla; its cause remains uncertain. Inflammatory myelitis is possible, but the low-positive MOG antibody alone does not establish MOG antibody-associated disease (MOGAD). A spinal arteriovenous fistula is an important alternative, although the reported negative catheter angiogram lowers its likelihood.
Our assessment: The new answer correctly calculates electrolyte-free water clearance, net water deficit, cation retention and the sodium trajectory, and preserves uncertainty about untreated AVP function. It still omits the supplied nitrogen-pool reconciliation, and its alternatives wording conflates recurrent central deficiency with desmopressin resistance.
Read the actual answer excerpts
OpenEvidence · 8.0/10
Supplied OpenEvidence answer; original run date and settings unverified
Reconciling the fluid balance. The chart's apparent +400 mL/day balance (intake 5.3 L − urine 4.8 L − stool 0.1 L = +0.4 L) ignores the audited net unmeasured loss (insensible loss minus metabolic water) of 0.6 L/day. True balance is therefore 0.4 − 0.6 ≈ −0.2 L/day, matching almost exactly the measured fall in total body water (42.2→41.8 L over 48 hours ≈ −0.2 L/day). So opinion 2 is right that there is an unrecorded loss — it is insensible loss (fever, tachypnoea/ventilation, sepsis), not renal water retention.
Contiguous excerpt.
MontMedical · 8.5/10
Current MontMedical Pro · 17 November 2026 · selected retry
The positive charted balance does not require an additional hidden loss: 5.30 L delivered minus 4.80 L urine and 0.10 L stool is +0.40 L/day, but subtracting the estimated 0.60 L net unmeasured loss gives −0.20 L/day, matching the estimated fall in total body water. Net sodium plus potassium retention is about 50 mmol/day: 420 delivered minus 360 in urine and 10 in stool. Assuming exchangeable sodium plus potassium is approximated by serum sodium times total body water, the preceding 158 × 42.0 plus 50, divided by 41.8, predicts about 160 mmol/L. The electrolyte-free water clearance is part of the urine already counted, not an extra loss to add.
Our assessment: Both identify the multisystem microvasculopathy. MontMedical better separates a suggestive phenotype from molecular confirmation; OpenEvidence makes some overly broad exclusions and speculative family-history inferences.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Review of the full evolution—renal, ocular, hepatic, and cerebral—points to a single multi-organ small-vessel disease rather than an isolated neuroinflammatory process.
Contiguous excerpt.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is the leading provisional diagnosis for this 44-year-old woman presenting with an 18-month progressive neurocognitive decline, pseudotumoral calcified brain lesions, occlusive retinopathy, premature vascular nephropathy, and cholestasis, pending TREX1 genetic confirmation. A tumefactive demyelinating disorder was initially considered, but microvascular hyalinosis without primary demyelination on biopsy, parenchymal calcifications, absent oligoclonal bands, and persistent enhancing lesions despite corticosteroids weigh strongly against it.
Our assessment: The new answer identifies an acquired IgG-associated capillary LPL-capture defect, leaves the antigen and transendothelial transport unproved, rejects direct anti-LPL attribution from the whole-plasma assay, and correctly recognises pseudohyponatraemia.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Acquired (autoimmune) chylomicronemia from a capillary‑surface LPL‑capture inhibitor — most consistent with anti‑GPIHBP1 antibody syndrome, not a true anti‑LPL antibody — is the best current explanation, and the "autoimmune anti‑LPL disease" label from the outside laboratory is not adequately supported.
Contiguous excerpt.
MontMedical · 9.0/10
Current MontMedical Pro · 17 November 2026 · selected retry
The whole-plasma mixing result does not establish an anti-LPL antibody, despite the 68% reduction in labelled substrate hydrolysis: the mixture could affect the assay through a plasma component or the substrate system rather than direct LPL inhibition. More specific experiments found no reproducible patient-IgG binding to human LPL in two assays and no reduction of purified LPL catalytic activity under the tested conditions. These results weigh strongly against the reported anti-LPL attribution, without identifying the source of the whole-plasma effect.
Our assessment: Both recognise the Fe-S enzyme pattern and deep-intronic testing gap. Neither fully establishes the genotype or completes the physiological proof chain.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Hereditary myopathy with lactic acidosis due to iron‑sulfur cluster assembly enzyme (ISCU) deficiency — a muscle‑specific disorder of mitochondrial Fe‑S cluster biogenesis — is the most likely diagnosis.
Contiguous excerpt.
MontMedical · 8.5/10
Historical MontMedical / Ark answer
Diagnostic assessment: Iron–sulfur cluster assembly deficiency (ISCU) myopathy is the leading provisional diagnosis, supported by lifelong exercise intolerance, recurrent rhabdomyolysis, severe exertional lactic acidosis, intramitochondrial iron accumulation, and selective muscle deficiency of iron–sulfur enzymes (succinate dehydrogenase and mitochondrial aconitase) with normal cytochrome-c oxidase. Definitive molecular confirmation remains unresolved because standard clinical exome sequencing covers only coding regions, missing deep-intronic ISCU mutations. Primary mitochondrial DNA or nuclear structural respiratory chain defects could cause hyperkinetic exertional lactic acidosis, but are weakened by preserved Complex IV and negative blood mitochondrial and exome sequencing. Additional findings During invasive cardiopulmonary exercise testing at the final 50-W stage, cardiac output rose from 5.0 L/min to 20.5
Our assessment: OpenEvidence explains the osmotic-fragility direction and downstream Gardos blockade more clearly. The MontMedical export corrects an erroneous initial description but retains presentation clutter.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Dehydrated hereditary stomatocytosis (hereditary xerocytosis), most consistent with a PIEZO1 mutation, accounts for the whole picture far better than HFE-related haemochromatosis — the compensated haemolysis, the dense/contracted red cells with reduced (not increased) osmotic fragility, the normal EMA binding, the disproportionate hepatic iron loading, and the temperature-dependent "pseudohyperkalaemia" all fit a cation-leak membranopathy rather than simple iron-loading from a single C282Y allele. [1-3]
Contiguous excerpt.
MontMedical · 8.0/10
Historical diagnostic-writer export; final displayed version unverified
The established syndrome is a chronic, predominantly unconjugated hyperbilirubinaemia with mild anaemia, reticulocytosis, raised LDH, undetectable haptoglobin, splenomegaly, pigment gallstones and iron overload, accompanied by a reproducible pseudohyperkalaemia that is temperature- and time-dependent in unseparated blood. The leading disease is a hereditary red-cell membrane disorder with increased osmotic fragility and a mild chronic haemolytic phenotype, most plausibly a dehydrated stomatocytic or xerocytic variant such as hereditary xerocytosis, rather than classical hereditary spherocytosis given the normal eosin-5-maleimide binding and the absence of a dominant spherocyte population. The single C282Y HFE allele does not by itself account for the degree of iron loading, and the reported paternal Gilbert syndrome history is a
Our assessment: The new answer distinguishes an IgG3-kappa-restricted pattern from one unique clonal protein, preserves possible contribution by the original clone, treats undetectable as below the assay limit, and does not use relapse to prove that the clone is incidental.
Read the actual answer excerpts
OpenEvidence · 8.0/10
Supplied OpenEvidence answer; original run date and settings unverified
Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) was the original diagnosis, and the month-12 flare most likely does not represent relapse of the original clone — the subgroup-specific light-chain staining instead points toward a polyclonal, immune-complex process that routine immunofluorescence (IF) cannot distinguish from true clonal deposition.
Contiguous excerpt.
MontMedical · 9.0/10
Current MontMedical Pro · 17 November 2026 · selected retry
The strong, reproducible IgG3κ restriction and matching serum isotype are meaningful evidence for a monoclonal-deposit lesion, but the variable-region experiment changes its interpretation. Both biopsies stained with all three κ subgroup reagents, whereas the patient's recombinant clone-derived immunoglobulin reacted with only one; competition, tissue controls, localization and repeated sections support a genuinely diverse deposit signal. Thus the deposits cannot be attributed exclusively to that clone, although it may contribute. Sequence-resolved analysis of microdissected deposits from both biopsies, compared with the known marrow/serum sequence and validated with appropriate standards and an independent targeted method, could test for that contribution and identify other deposited sequences. A match would establish presence, not by
Our assessment: Both recognise acquired brain sagging despite normal opening pressure. MontMedical gives a more precise localisation protocol and positive imaging criterion.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Frontotemporal brain sagging syndrome from spontaneous intracranial hypotension (SIH) — most plausibly due to an occult thoracic CSF-venous fistula — unifies this entire presentation far better than two coincidental diagnoses (bvFTD plus an incidental Chiari malformation). The comparison MRI is essentially diagnostic on its own: progressive tonsillar descent, a mammillopontine distance that has fallen from 8.1 mm to 3.2 mm, a pons flattening against the clivus with effacement of the prepontine cistern, and inferior displacement of the third-ventricular floor/chiasm are the classic signature of brain sagging from CSF volume loss, not a congenital hindbrain malformation. [1] Behavioural-variant frontotemporal dementia caused by SIH is well described, mimics bvFTD clinically and on
Contiguous excerpt: passage continues.
MontMedical · 9.0/10
Current MontMedical Pro · 17 November 2026
He has a progressive behavioural and executive syndrome with hypersomnolence, dysarthria, dysphagia and gait impairment. The leading unifying diagnosis is spontaneous intracranial hypotension with brain-sagging dementia, provisionally from a spinal CSF leak or CSF-venous fistula. The acquired tonsillar descent, reduced mammillopontine distance, flattened pons and inferior displacement of the third-ventricular floor and optic chiasm strongly challenge a congenital, separate Chiari explanation. PET demonstrates frontotemporal hypometabolism, but does not establish frontotemporal neurodegeneration as its cause.
Our assessment: Both diagnose afferent baroreflex failure. OpenEvidence more clearly explains preserved stress tachycardia alongside absent reflex compensation.
Read the actual answer excerpts
OpenEvidence · 9.0/10
Supplied OpenEvidence answer; original run date and settings unverified
The pattern here is classic for afferent baroreflex failure (ABF), most likely radiation-induced given the bilateral neck chemoradiation 15 years ago and the carotid wall thickening/plaques found on ultrasound. In ABF, loss of inhibitory input from the carotid sinus baroreceptors (via damaged cranial nerves IX/X) leaves cortical sympathetic outflow unopposed, so even trivial emotional or physical triggers produce paroxysmal, parallel rises in blood pressure and heart rate — exactly what this man's ambulatory monitoring shows during the phone call (241/128 mmHg, HR 129). [1-3] Between surges, baroreflex-cardiovagal failure and loss of buffering produce orthostatic and postprandial hypotension, which can coexist with hypertensive crises in the same patient — this combination,
Contiguous excerpt: passage continues.
MontMedical · 8.5/10
Historical MontMedical / Ark answer
The provisional diagnosis is radiation-induced afferent baroreflex failure following remote bilateral neck chemoradiation fifteen years earlier, presenting over nine months with volatile paroxysmal hypertension, emotional tachycardia, and concurrent orthostatic hypotension. Pheochromocytoma is challenged by normal supine plasma free and 24-hour urinary fractionated metanephrines alongside negative cross-sectional imaging, though formal beat-to-beat autonomic testing remains pending.
Our assessment: Both identify APRT deficiency and the need to identify the crystals. OpenEvidence handles the transfusion-confounded enzyme assay but incorrectly treats normal serum urate as evidence against uric-acid stones.
Read the actual answer excerpts
OpenEvidence · 8.0/10
Supplied OpenEvidence answer; original run date and settings unverified
APRT deficiency with 2,8‑dihydroxyadenine (DHA) crystal nephropathy is the diagnosis that best unifies this entire history, and it has almost certainly been systematically mislabelled as calcium oxalate disease at every stage.
Contiguous excerpt.
MontMedical · 8.5/10
Historical MontMedical / Ark answer
Further evidence Diagnostic assessment: Adenine phosphoribosyltransferase (APRT) deficiency causing 2,8-dihydroxyadenine crystalline nephropathy is the leading provisional diagnosis, unifying her lifelong radiolucent nephrolithiasis, native-kidney failure, and recurrent pale brown to colourless birefringent crystal deposition in the allograft. Enteric oxalate nephropathy secondary to Roux-en-Y gastric bypass is a competing consideration supported by early post-transplant hyperoxaluria, but it does not account for her nephrolithiasis and progressive tubulointerstitial disease that began nearly two decades prior to bypass surgery. Additional findings Two allograft biopsies, twelve weeks apart, demonstrate tubular injury, intratubular and intracellular birefringent crystal deposition, focal giant-cell reactions, and progressive interstitial fibrosis. Although the patient developed a bleeding marginal ulcer requiring four units of
Our assessment: Both recognise transferable IgG inhibition and reject knockout-floor target proof. MontMedical more explicitly labels the entity proposed; OpenEvidence better explains epitope masking.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Acquired, antibody-mediated macrophage iron-export defect best explains this presentation — an autoimmune disorder of iron recycling that is distinct from, but can mimic, both hereditary iron-storage disease and anaemia of inflammation.
Contiguous excerpt.
MontMedical · 8.5/10
Historical MontMedical / Ark answer
The presentation indicates a proposed acquired, antibody-mediated macrophage iron export defect causing reticuloendothelial iron sequestration and severe microcytic anemia progressing over eighteen months, supported by immunoglobulin transfer of export inhibition to donor macrophages. Classic anemia of chronic disease is weakened by undetectable serum hepcidin-25, repeatedly normal CRP, and failure of hepcidin-neutralizing reagents to prevent patient-IgG export inhibition. Additional findings
Our assessment: Both recognise nodopathy despite axonal histology and post-exchange negative testing. OpenEvidence more specifically develops CNTN1 and the renal antigen-link investigation.
Read the actual answer excerpts
OpenEvidence · 9.0/10
Supplied OpenEvidence answer; original run date and settings unverified
This presentation and course are substantially more consistent with an IgG4 paranodal/nodal antibody-associated autoimmune nodopathy (most likely anti-CNTN1, or a closely related CNTN1/Caspr1-complex nodopathy) causing a combined nodo-glomerular syndrome, rather than classical CIDP coexisting with an unrelated, antigen-negative membranous nephropathy. Both the "treatment-resistant CIDP" label and the consultant's conclusion that a nonimmune neuropathy has been "established" are premature.
Contiguous excerpt.
MontMedical · 8.5/10
Historical MontMedical / Ark answer
Further evidence Diagnostic assessment: The leading diagnosis is an autoimmune nodopathy (anti-contactin-1 or anti-pan-neurofascin neuro-renal syndrome) manifesting as subacute sensory ataxia, coarse tremor, demyelinating neuropathy refractory to intravenous immunoglobulin, and concurrent PLA2R/THSD7A-negative IgG4 membranous nephropathy. Non-immune diabetic complications are weakened by rapid motor progression over five months, demyelinating conduction block, cytoalbuminologic dissociation, and subepithelial basement-membrane spikes without diabetic glomerulosclerosis; definitive serological confirmation requires testing banked pre-treatment serum. Additional findings A specialist nodal/paranodal antibody panel is reported negative. The laboratory confirms that its only specimen was collected the morning after the fifth exchange, following the corticosteroid course. Frozen serum collected before his first immunoglobulin infusion remains in a research biobank. Electrophysiological
Our assessment: Both correctly identify the platelet-confined fibrinolytic defect and the structural-variant blind spot of the panel.
Read the actual answer excerpts
OpenEvidence · 9.0/10
Supplied OpenEvidence answer; original run date and settings unverified
Quebec platelet disorder (QPD) is the diagnosis that unifies the phenotype and resolves the apparent contradiction between the two consultants.
Contiguous excerpt.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
Further evidence Diagnostic assessment: The clinical pattern of autosomal dominant delayed rebleeding after trauma, surgery, and dental procedures, alongside mild thrombocytopenia and unrevealing routine coagulation and plasma clot-lysis assays, indicates a platelet-dependent hyperfibrinolytic disorder characteristic of Quebec platelet disorder. Historical mild type 1 von Willebrand disease combined with mild thrombocytopenia is an inadequate primary explanation because severe delayed bleeding recurred despite supra-therapeutic VWF and factor VIII replacement and corrective platelet transfusion. Additional findings Although his absent aggregation to epinephrine was reported to be of uncertain clinical significance, abnormal platelet aggregation with epinephrine is a recognized feature reported in Quebec platelet disorder. Limits of interpretation Normal quantitative factor XIII, normal α₂-antiplasmin,
Our assessment: MontMedical identifies the resistance phenotype and the confounded petrosal sampling; no OpenEvidence response was supplied.
Read the actual answer excerpts
OpenEvidence · No supplied answer
No supplied OpenEvidence answer
No answer was supplied. No score has been inferred.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
Further evidence Diagnostic assessment: Presenting with longstanding hypertension, hyperandrogenism since her late teens, and severe mineralocorticoid excess, the biochemical hypercortisolism without catabolic stigmata supports a provisional diagnosis of primary generalized glucocorticoid resistance (Chrousos syndrome), pending confirmatory genetic testing of the glucocorticoid receptor gene (NR3C1). Additional findings The patient demonstrates severe hypokalemic metabolic alkalosis with renal potassium wasting and suppressed plasma renin and aldosterone concentrations, associated with marked hypertension. Three complete 24-hour urinary free cortisol measurements demonstrate marked elevation, yet late-night salivary cortisol and sleeping midnight serum nadirs remain strictly normal, coexisting with normal bone density, stable body mass index, and a complete absence of facial plethora, proximal weakness, striae, or
Our assessment: Both recognise spontaneous HIT. MontMedical preserves uncertainty about adrenal venous thrombosis and argatroban exposure; OpenEvidence treats underdosing as demonstrated.
Read the actual answer excerpts
OpenEvidence · 8.0/10
Supplied OpenEvidence answer; original run date and settings unverified
Spontaneous (autoimmune) heparin-induced thrombocytopenia syndrome best explains this presentation — extensive venous thromboembolism with a sharp platelet fall beginning on day 8 after an uncomplicated arthroplasty, a strongly positive IgG-specific PF4 ELISA, and a serotonin-release assay pattern that is textbook for this entity, despite no heparin ever having been given. [1-3] All three consultants' positions are incorrect, and the adrenal haemorrhage and digital ischaemia are complications of the same process rather than reasons to withhold anticoagulation.
Contiguous excerpt.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
The established syndrome is severe, rapid-onset thrombocytopenia with extensive venous thrombosis—proximal left-leg DVT with bilateral segmental pulmonary emboli—accompanied by bilateral adrenal enlargement with high attenuation, patchy enhancement and surrounding stranding reported as adrenal haemorrhage, and by hypotension, hyponatraemia, hyperkalaemia, hypoglycaemia, low cortisol with markedly elevated ACTH, and clinical improvement after hydrocortisone, saline and glucose. The leading disease is heparin-induced thrombocytopenia (HIT), type II, with associated adrenal haemorrhagic infarction and primary adrenal insufficiency; the strongly positive IgG-specific PF4/polyanion ELISA and the serotonin-release assay showing strong activation without added heparin, reproduced in a second donor, are the reported laboratory findings that make this the leading diagnosis, while the absence of identified heparin
Our assessment: MontMedical correctly distinguishes C-terminal fragments from intact FGF23. OpenEvidence miscalls a measurable 6 pg/mL result below quantification and labels biological fragment excess an assay artefact.
Read the actual answer excerpts
OpenEvidence · 7.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Why the FGF23 result is spurious. Laboratory A's "C-terminal" assay uses two antibodies that both bind epitopes on the carboxy-terminal side of the FGF23 cleavage site, so it detects both intact, biologically active FGF23 and inactive C-terminal fragments generated by proteolytic cleavage. Laboratory B's "intact" assay requires simultaneous binding on both sides of the cleavage site and therefore measures only full-length, bioactive hormone. Severe iron deficiency anaemia (ferritin 4 ng/mL, saturation 4%) increases FGF23 transcription and parallel furin-mediated cleavage, so C-terminal fragments rise while intact FGF23 stays normal or low — this is a well-documented, reproducible phenomenon. [1-4] That is exactly the pattern seen here: 248 RU/mL at laboratory A
Contiguous excerpt: passage continues.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
The established syndrome is chronic hypophosphatemic osteomalacia with bilateral metatarsal insufficiency fractures, an incomplete femoral-neck stress fracture, elevated bone-derived alkaline phosphatase, and a calculated TmP/GFR of 1.1 mg/dL below the age-adjusted range, accompanied by medullary nephrocalcinosis and recurrent calcium kidney stones. The leading disease is a tumor-induced osteomalacia-like FGF23-mediated hypophosphatemic disorder, though no convincing lesion was identified on somatostatin-receptor PET/CT or targeted anatomical imaging.
Our assessment: MontMedical better preserves coexistence and the motif-specific assay boundary. OpenEvidence mislabels the vestibular test and overstates some genetic and phenotypic conclusions.
Read the actual answer excerpts
OpenEvidence · 8.0/10
Supplied OpenEvidence answer; original run date and settings unverified
The phenotype reproduces the complete CANVAS triad: a length-independent, non-length-dependent sensory neuronopathy (globally absent sensory responses with preserved motor amplitudes/velocities/F-waves and no denervation), bilateral vestibular hypofunction (reduced vHIT gains with corrective saccades, markedly reduced bithermal calorics, and failure of visually enhanced VOR suppression — losing fixation and making corrective saccades during passive head rotation, which is among the most specific bedside/laboratory findings in CANVAS), and cerebellar dysfunction (broken pursuit, gaze-evoked nystagmus with a downbeat component, mild dysmetria, vermian atrophy). [1-6] Onset of imbalance in the sixth decade, oscillopsia that resolves with stationary gaze, and absent ankle reflexes with relatively preserved knee jerks are all typical. [1][4-5][7] The dry, spasmodic cough
Contiguous excerpt: passage continues.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
The established syndrome is a progressive, predominantly sensory ataxic ganglionopathy with prominent large-fibre proprioceptive loss, areflexia at the ankles, and a chronic non-length-dependent sensory pattern, accompanied by a vestibular syndrome documented on repeated video head-impulse testing and bithermal caloric testing. Sjögren disease is independently established by strongly positive anti-SSA/Ro on two platforms, Schirmer testing at 3 mm in five minutes, and an adequate labial salivary-gland biopsy showing focal lymphocytic sialadenitis with a focus score of 1.6 foci/4 mm², confirmed on expert rereview, with no relevant exclusion condition. The leading disease remains Sjögren disease, with the neurological syndrome attributed to Sjögren-associated sensory ganglionopathy; the vestibular findings and the older dry spasmodic
Our assessment: Both final assessments identify the stimulus-specific oxidase disorder. OpenEvidence explains the neutrophil–B-cell discrepancy more directly; MontMedical initially leads with Crohn disease before correcting its ranking.
Read the actual answer excerpts
OpenEvidence · 9.0/10
Supplied OpenEvidence answer; original run date and settings unverified
This pattern is most consistent with p40phox (NCF4) deficiency — an atypical, milder form of chronic granulomatous disease (CGD) that is specifically known to produce a normal PMA-stimulated DHR test despite a genuine, clinically significant NADPH-oxidase defect. [1-2]
Contiguous excerpt.
MontMedical · 8.5/10
Historical MontMedical / Ark answer
The established syndrome is steroid-dependent granulomatous colitis with perianal disease and an anal stricture, accompanied since childhood by recurrent superficial staphylococcal skin abscesses; the leading disease remains Crohn disease, which is the working diagnosis supported by the chronic active inflammation, crypt distortion, and noncaseating granulomas on serial biopsies, with no infectious cause identified despite repeated stains, cultures, and targeted investigations. The recurrent skin abscesses and the absence of liver abscesses, osteomyelitis, invasive mould disease, or recurrent severe pneumonia are reported features of his history, not independently diagnostic of an alternative syndrome.
Our assessment: MontMedical separates suspected tumour microvascular disease from unidentified aspirate cells and unproved vascular architecture. OpenEvidence overstates what the haemodynamics prove and incorrectly says transbronchial biopsy samples the wrong compartment.
Read the actual answer excerpts
OpenEvidence · 7.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Avoid transbronchial lung biopsy — it samples the wrong compartment for PTTM's defining lesion (fibrocellular intimal proliferation of small pulmonary arteries/arterioles) and adds procedural risk in a patient who is hypoxaemic, borderline hypotensive and thrombocytopenic; a surgical lung biopsy could show the diagnostic vascular architecture but carries substantial risk in this haemodynamically unstable patient and should be reserved if less invasive routes fail. [11-13][24-25]
Contiguous excerpt.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
The established syndrome is severe precapillary pulmonary hypertension with rapidly progressive right-heart failure, microvascular-appearing perfusion defects, and a consumptive microangiopathic process; the leading disease is an occult non-haematopoietic malignancy, most plausibly a gastric primary with pulmonary tumour microemboli, though no tissue diagnosis has been established. The reported observations supporting this syndrome include normal spirometry and lung volumes with a haemoglobin-corrected DLCO of 29% predicted, mean pulmonary artery pressure rising from 34 to 49 mmHg with a pulmonary artery wedge pressure of 8–9 mmHg, cardiac output falling from 3.8 to 2.9 L/min, pulmonary vascular resistance rising from 6.8 to 13.8 Wood units, two technically adequate CT pulmonary angiograms without acute filling
Our assessment: Both recognise acquired esterification inhibition, explain why the negative blot and failed depletion do not exclude an antibody, and separate IgG inhibition from attribution to the marrow clone.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
This is acquired lecithin–cholesterol acyltransferase deficiency (ALCATI) with features strongly suggestive of an antibody-mediated mechanism linked to the IgG-κ clone, but neither opinion A nor opinion B is fully justified by the data presented — the evidence for enzyme inhibition is suggestive, not proven, and the renal immunofluorescence findings do not settle the question of causality either way.
Contiguous excerpt.
MontMedical · 8.5/10
Historical MontMedical / Ark answer
The established syndrome is severe acquired HDL deficiency with markedly reduced HDL cholesterol, excess unesterified cholesterol, and an abnormal phospholipid/free-cholesterol-rich lipoprotein fraction, accompanied by nephrotic-range proteinuria with hypoalbuminemia and renal impairment, anemia with target cells, mild reticulocytosis and reduced haptoglobin, and an IgG-κ monoclonal protein. The leading disease is an acquired disorder of HDL metabolism, most plausibly a monoclonal gammopathy–associated or autoimmune form of severe HDL deficiency, with the kidney biopsy showing mesangial expansion, glomerular foam cells, vacuolated capillary wall material, and intramembranous and mesangial lipid-like inclusions; the archived normal HDL cholesterol and normal albumin/urinalysis eighteen months earlier establish this as an acquired process rather than a lifelong inherited HDL
Our assessment: MontMedical reaches the correct final diagnosis and addresses normal circulating flavins, but its initial length-dependent/ETF-led formulation is misleading. OpenEvidence prioritises the syndrome better, while overlooking that articulation-independent audiometry was already done.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Given the non–length-dependent pattern of weakness, absent reflexes without upper-motor-neuron signs, profound sensory neuronopathy, and an auditory neuropathy phenotype, this presentation fits far better with riboflavin transporter deficiency (Brown–Vialetto–Van Laere syndrome) than with motor neuron disease or confirmed multiple acyl-CoA dehydrogenase deficiency (MADD) — and each element of the draft discharge plan works against her.
Contiguous excerpt.
MontMedical · 8.0/10
Historical MontMedical / Ark answer
The established syndrome is a severe, length-dependent and regionally weighted motor neuronopathy with prominent bulbar, cervical and thoracic involvement, accompanied by a sensory neuronopathy and by auditory neuropathy spectrum physiology; the leading disease is a hereditary motor and sensory neuropathy with neuronopathy and auditory neuropathy, with the differential still open to a mitochondrial or other inherited neurometabolic disorder. The reported findings supporting this formulation are the low upper-limb motor amplitudes with relatively preserved velocities and no convincing conduction block or temporal dispersion, absent or severely reduced sensory responses, active and chronic denervation across bulbar, cervical and thoracic regions with relative leg sparing, absent reflexes with flexor plantars and no spasticity,
Our assessment: MontMedical explicitly distinguishes the factor-II preparation, late peptide cleavage, active thrombin, complex formation and clinical heparin response. OpenEvidence names the leading disorder but repeatedly describes the unproved resistance mechanism as established.
Read the actual answer excerpts
OpenEvidence · 7.5/10
Supplied OpenEvidence answer; original run date and settings unverified
The thrombin-generation and reconstitution experiments support this mechanism rather than refute it. A reduced peak with a disproportionately high software-reported area under the curve and substrate cleavage persisting well beyond the control is the signature described for arginine-596 (and related) prothrombin variants: the mutant thrombin is generated and continues cleaving chromogenic substrate for longer because antithrombin cannot efficiently inactivate it, which can inflate automated ETP/AUC calculations that assume normal thrombin decay kinetics. [5] Depletion/reconstitution confirms the defect travels with the patient's prothrombin molecule itself (abnormal curve with patient factor II in normal plasma; near-normalization with patient plasma plus control factor II), and the lower thrombin–antithrombin complex signal when patient-derived factor
Contiguous excerpt: passage continues.
MontMedical · 9.5/10
Historical MontMedical / Ark answer
He has recurrent apparently unprovoked venous thromboembolism, with bilateral pulmonary emboli and a proximal left-leg DVT; the strong paternal history and absence of a bleeding phenotype are notable. The leading provisional diagnosis is familial dysprothrombinemia, with a qualitative prothrombin abnormality more likely than a simple deficiency: factor II activity is repeatedly low despite normal antigen in him, his sister and his father, and the patient-derived factor II preparation reproduces the low peak and prolonged tail.
Our assessment: MontMedical separates preserved enzyme assembly and heparin binding from untested endplate retention, and low-positive antibody detection from pathogenicity. OpenEvidence prematurely declares the antibody false and the precise MuSK-interaction defect localised.
Read the actual answer excerpts
OpenEvidence · 8.0/10
Supplied OpenEvidence answer; original run date and settings unverified
The "positive" AChR antibody is a false positive. A RIPA titre only modestly above the laboratory cut-off (0.74–0.81 nmol/L), with no binding on an independent live clustered-AChR cell-based assay, is the pattern expected when RIPA low-titre positivity does not reflect true pathogenic antibody. Live cell-based assay is more sensitive and specific than RIPA for genuine low-affinity AChR antibodies, and RIPA-positive/CBA-negative results in this titre range are increasingly recognised as assay artefact rather than preclinical or evolving autoimmune disease. [2-4]
Contiguous excerpt.
MontMedical · 9.5/10
Current MontMedical Pro · 17 November 2026
She has a neuromuscular-junction syndrome with fatigable weakness, decrement on repetitive stimulation, and a second CMAP after one nerve stimulus. The leading provisional diagnosis is COLQ-related congenital myasthenic syndrome, likely involving impaired endplate localization or retention of acetylcholinesterase: miniature endplate currents are prolonged, while sampled receptor openings and acetylcholinesterase catalytic activity are not. Sustained hypoventilation is an established respiratory complication. The low-positive AChR antibody does not by itself establish autoimmune myasthenia; the negative live cell-based assay does not prove the radioimmunoprecipitation result false.
Our assessment: MontMedical separates the exact published JAK3 association, unknown carrier-cell identity and unproved drug responsiveness. OpenEvidence gets the entity right but prematurely labels the blood signal incidental and the disease GI-confined.
Read the actual answer excerpts
OpenEvidence · 8.0/10
Supplied OpenEvidence answer; original run date and settings unverified
JAK3 p.Lys563_Cys565del is the specific recurrent activating variant already reported in multiple iNKLPD-GI series and is considered the molecular signature supporting the neoplastic (rather than purely reactive) nature of this entity, acting through JAK3–STAT5 pathway activation. [1-2][16-17] Detecting it at similar allele fractions in two independent GI sites, confirmed orthogonally and absent from germline (buccal) DNA, fits this pattern rather than indicating a separate aggressive process. The low-level peripheral-blood detection (0.6–0.8% VAF) with normal blood counts and no abnormal population on routine flow cytometry does not meet criteria for T- or NK-LGL leukaemia, which requires a persistent (>6 months), flow-demonstrable clonal expansion of LGLs in blood, usually with cytopenias. [7][18-21]
Contiguous excerpt: passage continues.
MontMedical · 9.5/10
Historical MontMedical / Ark answer
The exact JAK3 p.Lys563_Cys565del alteration, equivalently K563_C565del, has been reported in NK-cell enteropathy: an original biopsy-sequencing study detected it in 3 of 10 patients. This association is relevant to the favoured classification, but it does not assign this patient's mixed-sample variant to atypical NK cells or predict JAK-inhibitor benefit.
Our assessment: MontMedical corrects both resistance inputs and obtains PVR 1.74 WU. OpenEvidence calculates pulmonary flow correctly later, but keeps thermodilution output in the resistance calculation and incorrectly labels combined pre/post-capillary disease.
Read the actual answer excerpts
OpenEvidence · 6.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Original (end-diastolic wedge) Corrected (mean wedge) 39 mmHg 39 mmHg 13 mmHg 26 mmHg 26 mmHg 13 mmHg 4.1 L/min 4.1 L/min 6.3 WU 3.2 WU Apparent pre-capillary PH Post-capillary PH (combined pre-/post-capillary, PVR >3 WU with PAWP >15 mmHg) This reclassifies her from apparent Group 1 pulmonary arterial hypertension to pulmonary hypertension due to left heart disease, combined pre- and post-capillary phenotype (mPAP ≥20 mmHg, PAWP >15 mmHg, PVR ≥3 WU). [1][3] Direct left atrial recording confirming the wedge trace, and the absence of a sustained LA–LV diastolic gradient, exclude mitral stenosis as the cause of the high wedge pressure — the V wave reflects loss of atrial reservoir
Contiguous excerpt: passage continues.
MontMedical · 9.5/10
Historical MontMedical / Ark answer
The original calculation does not support presumed pulmonary arterial hypertension: end-diastolic wedge pressure of 13 mmHg must be replaced by full-cycle mean wedge pressure of 26 mmHg. Thermodilution cardiac output of 4.1 L/min must be replaced by oxygen-Fick pulmonary flow, because resistance across the pulmonary circulation uses pulmonary rather than systemic flow. Calculated resting pulmonary flow is 7.46 L/min, systemic flow is 4.52 L/min, Qp:Qs is approximately 1.65, and PVR is (39−26)/7.46 = 1.74 Wood units. Thus, the original high-resistance calculation is not a supported diagnostic rationale for starting tadalafil. Crossing an exercise wedge-pressure threshold establishes abnormal pulmonary venous pressure, not ordinary LV diastolic dysfunction as the entire cause. During
Our assessment: Both identify CANOMAD and reject the initial CSF result as proof of infiltration. MontMedical quantifies expected blood carryover and preserves the unproved identity of the antibody-producing clone; OpenEvidence assumes that clone is the source.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
The unifying diagnosis is CANOMAD/CANDA — chronic ataxic neuropathy with ophthalmoplegia (or bulbar) attacks due to IgM monoclonal antibodies against disialosyl ganglioside epitopes (GD1b, GT1b, GQ1b), arising from a low-burden MYD88-mutated IgM clone — not CNS lymphoplasmacytic infiltration, and not an anti-MAG neuropathy. The chronic, vision-dependent sensory ataxia with pseudoathetosis, absent reflexes, preserved strength between attacks, and relapsing-remitting ophthalmoplegia/bulbar/facial weakness with normal repetitive stimulation and a non-uniform (mixed axonal-demyelinating) electrophysiological pattern is the classic CANOMAD phenotype, usually driven by an IgM-MGUS-associated monoclonal gammopathy of clinical significance even when the paraprotein level and marrow burden are modest. [1-4]
Contiguous excerpt.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
The concordant tube-1 flow, MYD88 and IGH results do not establish that the detected clone originated within the CNS. Calculated from the paired counts, proportional blood admixture predicts approximately 8.3 clonal cells in the 2.0-mL aliquot and a whole-nucleated-cell mutant allele fraction of approximately 0.025%, close to the nine observed events and reported 0.03%. Because that same clonotype circulates in blood, matching IGH adds identity information but does not resolve its anatomical source in this traumatic specimen. The anti-MAG ELISA does not establish anti-MAG neuropathy as the primary explanation: its 1,900-BTU result lies within the published diagnostic grey area despite exceeding the manufacturer's 1,000-BTU cutoff. Negative reference tissue confirmation and
Our assessment: Both identify the FV-short mechanism. MontMedical explains why co-depletion does not isolate either protein and proposes controlled V1-versus-wild-type RNA testing; OpenEvidence treats the candidate variant and exact cooperative mechanism as already proved.
Read the actual answer excerpts
OpenEvidence · 8.0/10
Supplied OpenEvidence answer; original run date and settings unverified
The unifying synthesis: V1 causes partial exon‑13 skipping; the resulting short FV protein binds and stabilises TFPIα; elevated TFPIα (86 ng/mL here, versus 5–12 ng/mL control) suppresses prothrombinase assembly during the initiation phase. This explains why thrombin generation is markedly reduced with a weak TF trigger (18%) but near‑normalises with a strong trigger (79%), and why a TFPIα‑neutralising antibody restores generation to 92% — mirroring findings in the only other reported FV East Texas kindred, where thrombin generation was restored in vitro by either an anti‑TFPI antibody or factor VIIa. [3] It also explains the routine labs: one‑stage PT/APTT reagents and single‑factor assays are not designed to detect excess TFPI,
Contiguous excerpt: passage continues.
MontMedical · 9.5/10
Current MontMedical Pro · 17 November 2026
The capture experiment localises transferable suppression to a preparation containing both short FV and TFPIα; co-depletion and unequal component concentrations prevent assigning it to either protein alone. Purified short FV without TFPIα did not reproduce excess suppression and retained activated prothrombinase function, arguing against the proposed intrinsic inhibitor, but not against a carrier or cofactor role. Reconstitute control and depleted plasma with independently matched short FV, TFPIα and protein S, alone and in combination, with recovery controls, and measure thrombin generation and FV prothrombinase function. Excess suppression only with the combination would support cooperation; suppression matched by TFPIα alone would favor an inhibitor-quantity explanation.
Our assessment: Both recognise acquired EPP and transfusion dilution. MontMedical also reconciles the zinc-protoporphyrin denominator and FECH dosage quantitatively; OpenEvidence overassigns the deletion to the SF3B1 clone and calls combined-treatment worsening causal.
Read the actual answer excerpts
OpenEvidence · 8.0/10
Supplied OpenEvidence answer; original run date and settings unverified
The erythroblast-enriched marrow fraction makes the mechanism explicit: FECH copy dosage of 0.60 (vs. 1.00 in diploid fibroblasts/lymphocytes) implies roughly 66–80% of that fraction is deletion-bearing, consistent with the parallel shift in the c.315-48C allele fraction from the expected 50% to 83%. Because the retained chromosome carries the low-expression hypomorphic C allele, the deletion-bearing clone is left hemizygous for the hypomorphic allele alone — functionally reproducing the classic trans "null mutation + IVS3-48C" genotype that defines symptomatic inherited EPP, but acquired somatically and confined to the erythroid clone. [8][10] This explains why PPIX overproduction is severe despite the deletion alone predicting only ~50% loss of FECH activity.
Contiguous excerpt.
MontMedical · 9.5/10
Historical MontMedical / Ark answer
The local result is not a separate measurement of metal-free protoporphyrin: its unseparated hematofluorometry channel is calibrated to zinc protoporphyrin and reports per whole blood. Using the paired haematocrit of 0.28, the reference result gives 6,400 × 0.06 × 0.28 = 107.5 µg/dL whole blood of zinc-bound protoporphyrin, close to the local 113. Total protoporphyrin instead corresponds to 1,792 µg/dL whole blood. Thus the reassuring-looking local number is consistent with measuring mainly the minor zinc fraction; it cannot overturn validated fractionation. The marrow findings strongly support an acquired, erythroid-enriched FECH deletion retaining the low-expression c.315-48C allele. With normal cells carrying two copies and deleted cells one, dosage 0.60 implies approximately
Our assessment: Both distinguish the resolved fluid episode from acquired ON-bipolar dysfunction and identify the knockout floor effect, total-IgG specificity gap and artificial delivery route. Treatment recommendations are outside this diagnostic score.
Read the actual answer excerpts
OpenEvidence · 9.0/10
Supplied OpenEvidence answer; original run date and settings unverified
None of the four positions at the meeting is fully supportable; the case is best explained as melanoma-associated retinopathy (MAR) — an acquired, antibody-mediated ON-bipolar-cell dystrophy that began before either drug was started — occurring alongside, but mechanistically separate from, the self-limited MEK-inhibitor serous retinopathy that has already resolved. The familial TRPM1 variant, the "negative" live-cell antibody assay, and the mouse intravitreal-injection experiment are all being over-read in one direction or another.
Contiguous excerpt.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
The key unresolved distinction is whether TRPM1-reactive IgG specifically mediates the retinal dysfunction and whether it can act in the patient’s intact retina: the mouse result used total IgG plus carrier, and the knockout b-wave was already at floor. TRPM1-specific depletion with mock-depletion and add-back comparisons would test specificity. The worsening vision during pembrolizumab coincides with tumour response, but the supplied evidence does not establish that pembrolizumab caused it or that the experimental result proves the antibody’s route of action in this patient.
Our assessment: Both correctly accept the pathogenic CPT2 genotype. MontMedical recognises that malonyl-resistant mixed activity has not been validated as native CPT II activity; OpenEvidence repeatedly treats it as CPT-II-specific and infers an enzyme deficit from it.
Read the actual answer excerpts
OpenEvidence · 7.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Why the laboratory's rebuttal doesn't hold up. The "uninhibited total CPT activity" in a disrupted homogenate is dominated by CPT1, which is unaffected in this patient — a normal total (105%) tells us almost nothing about CPT2. The laboratory's own malonyl-CoA experiment, which is the better proxy for CPT2-specific activity, shows the opposite of what their note claims: the malonyl-CoA-resistant fraction falls from 54% in controls to 6% in the patient — a severe, genotype-concordant CPT2 deficit, not reassurance. Ninety-six percent protein abundance does not equal normal function; this is exactly the Ser113Leu mechanism described since 1993 — normal synthesis, abnormal stability/catalysis. [2] The 15-minute, 40 °C heat-challenge performed in
Contiguous excerpt: passage continues.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
Normal glucose and measurable ketones do not show that he can sustain long-chain fatty-acid oxidation while vomiting and catabolic. The ordered 5% glucose at 80 mL/hour provides only 4 g carbohydrate/hour; either proposed higher-concentration infusion provides 16 g/hour. At that equal carbohydrate delivery, 10% at 160 mL/hour adds 3.84 L/day, versus 1.92 L/day with 20% at 80 mL/hour. Carbohydrate provision therefore needs urgent revision alongside glucose and electrolyte monitoring, an insulin plan if needed, total fluid balance and renal assessment—not an unmonitored increase in volume. The earlier normal findings address different questions, not a shared exclusion of CPT II deficiency. Appropriate forearm lactate and ammonia rises while well weigh against
Our assessment: Both explain the non-exclusionary gradient and inadequate biopsy. MontMedical correctly dates the thrombus from the prior patent scan; OpenEvidence introduces an unproved older thrombotic component and overstates azathioprine causation.
Read the actual answer excerpts
OpenEvidence · 8.0/10
Supplied OpenEvidence answer; original run date and settings unverified
The overall picture is azathioprine-induced porto-sinusoidal vascular disorder (PSVD, formerly idiopathic non-cirrhotic portal hypertension/nodular regenerative hyperplasia) that has been mislabelled as "cryptogenic cirrhosis," and the new 60% occlusive portal-vein thrombus extending into the SMV is an acute-on-chronic event that meets standard criteria for prompt therapeutic anticoagulation — not observation, a 4–6 week delay, the rivaroxaban regimen as proposed, or reflexive thrombolysis/TIPS. [1-3]
Contiguous excerpt.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
The measured hepatic venous pressure gradient was 9 minus 5, or 4 mmHg, but it does not exclude the portal hypertension demonstrated by his varices. Repeating the pressures three times established reproducibility under the same conditions, not an adequately isolated wedge: contrast escaped from the occluded territory into a freely draining accessory hepatic vein, which could depress the wedged reading. Moreover, a presinusoidal process can yield a near-normal hepatic venous gradient. If pressure measurement would change care, an appropriately isolated measurement in another suitable vein, or controlled occlusion of the communication, would address this defect. The biopsy found no obvious bridging fibrosis in its sampled tissue, but the later description
Our assessment: Both correctly convert haemoglobin percentages and oxygen delivery. OpenEvidence more directly interprets the partial-C genotype; MontMedical initially keeps anti-Jkb plausible despite verified Jkb-negative units, then correctly downgrades it later.
Read the actual answer excerpts
OpenEvidence · 9.5/10
Supplied OpenEvidence answer; original run date and settings unverified
The Rh genotype finding is neither "incidental" nor "proof" — both framings overreach. RHDDIIIa‑CE(4‑7)‑D is a hybrid allele, and the absence of any conventional RHCECe/CE allele means this patient does not carry a gene encoding full, conventional C antigen; her serologic "C-positive" result reflects a partial/hybrid Rh protein. Patients with partial Rh antigens can form alloantibodies against epitopes of the conventional antigen they lack despite serotyping antigen-positive — the same mechanism well documented for partial D causing anti-D in D-positive-typed patients with sickle-cell disease, sometimes after a single exposure. [8] This is a recognised limitation of serologic Rh/K "matching" in sickle-cell disease, which molecular RH genotyping is increasingly used to
Contiguous excerpt: passage continues.
MontMedical · 8.5/10
Historical MontMedical / Ark answer
She has severe intravascular haemolysis with marked reticulocytopenia, and her haemoglobin has fallen below its pretransfusion level. The leading provisional diagnosis is a delayed haemolytic transfusion reaction with hyperhaemolysis: HbA fell from 39% on day 7 to 6% on day 10 as total haemoglobin fell, alongside haemoglobinuria and biochemical haemolysis. Rising lactate, myocardial injury and acute kidney injury are established organ complications. An evanescent anti-Jkᵇ is plausible despite Jkᵇ-negative units; the RH variant also merits review of C matching, but neither establishes the cause.
Our assessment: Both reject scan/genotype/amenability as independent proof of amyloid or Fabry disease. MontMedical better specifies expert review for curvilinear bodies; OpenEvidence is too categorical that negative sampled myocardium excludes all cardiac amyloid.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
A grade 3 PYP scan has very high sensitivity for ATTR-CM, but its diagnostic algorithm is only valid when a monoclonal protein screen is first excluded — PYP cannot be used alone to "establish" ATTR-CM once a monoclonal gammopathy is present, and recognised causes of false-positive scintigraphy include AL amyloidosis itself, prior infarction, and hydroxychloroquine toxicity. [1][1] A negative TTR genotype does not exclude amyloidosis either, since most ATTR-CM is wild-type, non-hereditary disease — so claim 1 and the "negative gene test excludes it" statement both misread the algorithm. More decisively, six endomyocardial samples were Congo-red negative with appropriate controls; cardiac biopsy is the reference standard and a well-sampled negative
Contiguous excerpt: passage continues.
MontMedical · 9.0/10
Current MontMedical Pro · 17 November 2026
The key unresolved distinction is hydroxychloroquine toxicity versus Fabry-related storage; expert review of retained tissue should assess the full inclusion morphology, particularly for curvilinear bodies and other diagnostic features. The recurrent complete block warrants pacing without waiting for aetiological treatment; with LVEF 42% and anticipated high pacing burden, device strategy should account for potential pacing-related dysfunction.
Our assessment: Both reconstruct the 21.1% to 2.5% blood VAF, the approximately 13% sampling-miss probability, and the different implications of monosomy 7 and copy-neutral rescue. Both correctly reject blood-only clearance of the related donor.
Read the actual answer excerpts
OpenEvidence · 9.0/10
Supplied OpenEvidence answer; original run date and settings unverified
This is a single unifying diagnosis — germline SAMD9L‑related ataxia‑pancytopenia syndrome that has evolved a maladaptive, SETBP1‑mutated monosomy‑7 clone — not "sporadic hypocellular MDS plus an unrelated neurological disorder." The childhood cytopenias, adolescent‑onset cerebellar ataxia with white‑matter change, the mother's mild gait disorder with normal counts, and the uncle's fatal "aplastic anaemia" are the recognised multigenerational phenotype of a dominant germline SAMD9L gain‑of‑function variant, which produces cerebellar atrophy/ataxia together with a marrow that is prone to monosomy 7 and transformation. [1-3] The marrow now shows multilineage dysplasia with rising blasts (1%→7%) on a persistently hypocellular background with transfusion dependence — this is myelodysplastic syndrome with excess blasts arising in a
Contiguous excerpt: passage continues.
MontMedical · 9.0/10
Historical MontMedical / Ark answer
The key unresolved donor question is whether his sister carries the familial variant constitutionally or has blood-cell selection masking it. Her blood result excludes only variant fractions at or above 10%; nonhaematopoietic testing, alongside assessment for chromosome-7 copy-neutral loss of heterozygosity in blood, is needed. Saliva, sorted T cells and EBV-transformed cells are not equivalent substitutes. At 2.5% variant frequency, 80 molecules have about a 13% chance of missing the variant entirely; greater depth alone does not fix a policy that excludes low-frequency calls.
Our assessment: Both identify transferable IgG-mediated signalling inhibition and inducible macrolide resistance. MontMedical keeps assay interference separate from biological inhibition and avoids assigning the relapse chiefly to either host or organism; OpenEvidence overstates that relative attribution.
Read the actual answer excerpts
OpenEvidence · 8.5/10
Supplied OpenEvidence answer; original run date and settings unverified
Drug Result Interpretation Clarithromycin, day 3 MIC 0.5 µg/mL Misleadingly low early reading Clarithromycin, day 14 MIC >16 µg/mL True resistance — erm(41) T28 is the functional sequevar causing inducible macrolide resistance, only unmasked on extended incubation [7-8] Linezolid MIC 32 µg/mL Resistant by CLSI-based method Amikacin MIC 8 µg/mL Susceptible, but clinical relapse occurred despite this on the first course Imipenem MIC 4 µg/mL Susceptible Clofazimine, tigecycline MIC 0.25 µg/mL each No validated breakpoint; descriptive only, but clofazimine has documented synergy with amikacin and prevents emergence of amikacin resistance [7] Switching azithromycin to clarithromycin is not a rational fix — both are macrolides and erm(41)-mediated inducible resistance affects the
Contiguous excerpt: passage continues.
MontMedical · 9.5/10
Current MontMedical Pro · 17 November 2026
The initial TB release assay is indeterminate, not negative: the mitogen-minus-nil response is only 0.02 IU/mL, so the positive control failed. The cell-free spike experiment shows that patient IgG can make IFN-γ poorly recoverable by that immunoassay; it does not establish that her T cells cannot produce IFN-γ. Separately, the monocyte experiment demonstrates biological signalling inhibition, so the abnormalities are not merely analytical. Tissue TB PCR was negative in the sampled lesion, but neither it nor this indeterminate release assay excludes tuberculosis elsewhere or establishes latent TB status. A cellular production assay using washed cells and an unaffected detection method could clarify production.
MontMedical's strongest advantage in this collection is precise interpretation of experiments. Examples include separating factor-II preparation effects from demonstrated thrombin resistance in case 43, correcting both pulmonary-resistance inputs in case 46, and distinguishing the documented JAK3 disease association from unidentified carrier cells in case 45. The new renal-deposit answer also preserves possible clonal contribution instead of declaring the clone incidental.
MontMedical still has a concrete consistency problem in case 22. The main evidence review appropriately reopens the vascular differential; the alternatives section gives conflicting reasons against it. Case 16 also contains an initial viral-ratio wording error corrected later, and case 23 omits a useful nitrogen-pool reconciliation. These limitations remain part of the displayed assessments.
Updated paired means: MontMedical 8.83/10; OpenEvidence 8.17/10. This review favours MontMedical on these selected answer texts. Its retrospective selection, mixed versions, targeted retries and unblinded scoring limit any broader claim about comparative diagnostic accuracy or clinical benefit.